News & Research
New studies, trials, regulatory changes and news about the compounds on Amino WRX. Items are collected automatically once a day and summarised by AI; they are not reviewed by an editor before they appear here. Read the original source before relying on anything.
Last updated 2026-10-17.
- New compoundZenagamtide2026-10-16A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication (recruiting)
ClinicalTrials.gov
A second recruiting trial is testing how adults with overweight or obesity, with or without type 2 diabetes, tolerate switching from semaglutide to zenagamtide. The listing covers tolerability after a switch and does not report outcomes.
- New compoundZenagamtide2026-10-16A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication (recruiting)
ClinicalTrials.gov
A recruiting trial is testing how adults with overweight or obesity, with or without type 2 diabetes, tolerate switching from tirzepatide to zenagamtide. It is a switch-tolerability study and has not reported weight or safety outcomes.
- New compoundVK27352026-10-14Viking Starts Phase 3 SUNRISE Program for Oral VK2735 in Obesity
BioPharm International
Viking Therapeutics has started Phase 3 SUNRISE trials of oral VK2735, a dual GLP-1/GIP agonist, for obesity. Each of two 68-week studies, one with type 2 diabetes and one without, plans to enroll 560 adults, and this report does not include efficacy results.
- New compoundretatrutide2026-10-13Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame?
CBS News
Two unverified FDA adverse-event reports name unapproved retatrutide from unofficial sources in connection with deaths, and causation has not been established. Poison centers also logged 862 retatrutide exposures in the three months ending September.
- New compoundpetrelintide2026-10-13Bootleg Retatrutide Deaths? PMOS and Dementia; Weight-Loss Drug to Be Discontinued
MedPage Today
A phase 2 trial of Zealand’s amylin analog petrelintide found up to 9.2% weight loss at 28 weeks, compared with 2% on placebo, in people with overweight or obesity and type 2 diabetes. That is early human evidence for another amylin-pathway peptide being studied for weight loss.
- New compoundretatrutide2026-10-12The Lancet
The Lancet
The Lancet pointed to TRIUMPH-2, in which retatrutide reduced body weight and improved glycemic and cardiometabolic measures in people with obesity and type 2 diabetes. Journal publication is a major human-results milestone for this unapproved triple agonist.
- New compoundPetrelintide2026-10-07Zealand, Roche’s obesity drug helps patients lose up to 9.2% weight in mid-stage trial
Reuters
Once-weekly petrelintide, an amylin-analog peptide, produced 7.4 to 9.2 percent weight loss at 28 weeks, compared with about 2 percent for placebo, in 220 adults with overweight or obesity and type 2 diabetes. Gastrointestinal dropouts were similar to placebo, and a Phase 3 program in about 7,000 people is already underway.
- New compoundPetrelintide2026-10-07ZUPREME-2: Petrelintide outperforms placebo for weight loss in T2D and obesity
HCPLive
A report on the ZUPREME-2 trial says petrelintide also lowered HbA1c by 0.61 to 0.88 points more than placebo in adults with type 2 diabetes and obesity. No unexpected safety signals were described alongside the weight-loss result.
- New compoundPetrelintide2026-10-06Petrelintide Yields Up to 10.7% Weight Loss With Mild GI Effects
Pharmacy Times
A phase 2 trial published in The Lancet Diabetes & Endocrinology found that petrelintide, a long-acting amylin analog, produced up to 10.7% weight loss at 42 weeks. Nausea was mostly mild and occurred mainly during dose escalation.
- EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
Pharmacy Times
The same phase 2b of eloralintide plus tirzepatide cut HbA1c by up to 2.9% in adults with obesity and type 2 diabetes. Adverse-event discontinuations were 10.8% to 27% when both drugs were escalated together, which is the tolerability figure to show if the combination is mentioned.
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
CNBC
Eloralintide, a selective amylin agonist not in the catalogue, plus tirzepatide produced up to 23.3% weight loss at 48 weeks in obesity with type 2 diabetes, and Lilly plans phase 3 by year-end. The site should flag the new peptide and should not paste the combination result onto tirzepatide monotherapy.